Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
504 questions in 57 reviews · Kidney and Transplant
current versionsNo studies 504 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Low vs standard dose valganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane | no estimate extracted | NR | No studies |
Low vs standard dose valganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane | no estimate extracted | NR | No studies |
Maribavir vs ganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane | no estimate extracted | NR | No studies |
Maribavir vs ganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs placebo or no treatment Death (any cause) · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Tonsillectomy plus standard care vs standard care > 50% increase in SCr · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs placebo or no treatment Remission of haematuria · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs placebo or no treatment Relapse of proteinuria · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs placebo or no treatment > 50% increase in SCr · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs other supportive care treatment Death · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Early graft loss ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Delayed graft function ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Acute rejection ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Ureteric complications ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Kidney function at one year ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Doubling of SCr · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Fatal or nonfatal stroke · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Doubling of SCr · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Fatal or nonfatal stroke · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Micro‐ to macroalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Micro‐ to normoalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB Doubling of SCr · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB Fatal or nonfatal stroke · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB Micro‐ to macroalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB Micro‐ to normoalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone All‐cause death · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone Cardiovascular death · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone Doubling of SCr · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone Fatal or nonfatal stroke · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone Micro‐ to macroalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone Micro‐ to normoalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospitalisation Home versus in‐centre haemodialysis for people with kidney failure (2024) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Major bleeding Median · adults with kidney failure treated with long‐term HD Anticoagulation for people receiving long‐term haemodialysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Minor bleeding Median · adults with kidney failure treated with long‐term HD Anticoagulation for people receiving long‐term haemodialysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Blood transfusion · adults with kidney failure treated with long‐term HD Anticoagulation for people receiving long‐term haemodialysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs mechanical thrombectomy Access dysfunction · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs mechanical thrombectomy Successful dialysis · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Mechanical thrombectomy vs pulse spray technique Access dysfunction · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Mechanical thrombectomy vs pulse spray technique Successful dialysis · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Mechanical thrombectomy vs continuous infusion Failure · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Mechanical thrombectomy vs continuous infusion Access dysfunction · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |